Sign In

November 4, 2014
The current state of hepatitis C services in England is unacceptable and a clear action plan is essential to reduce current and impending burden on the health service, save money and most...
November 3, 2014
Relapse of chronic hepatitis C virus (HVC) genotype 1 (GT-1) after initial treatment with sofosbuvir plus ribavirin therapy can be effectively re-treated with a combination of sofosbuvir plus...
October 31, 2014

Preparing for our upcoming annual meeting in Boston has AASLD staff, leadership, and committees working frantically to get ready.

October 30, 2014

On October 17 In Washington, DC, the Patient-Centered Outcomes Research Institute (PCORI) has invited AASLD to participate in a meeting to discuss the clinical issues related to choosing treatments for hepatitis C infection.

October 29, 2014
A major pan-European survey into the burden of gastrointestinal (GI) disorders and the delivery of care has revealed changing trends in many important GI and liver diseases and worrying...
October 29, 2014
Approximately 1 billion people worldwide have non-alcoholic fatty liver disease (NAFLD). Individuals with this disease have an increased risk of type 2 diabetes, obesity, and kidney disease.
October 29, 2014
A hinge in the RNA genome of the virus that causes hepatitis C works like a switch that can be flipped to prevent it from replicating in infected cells.
October 28, 2014
In a group of young users of injection drugs, recent maintenance opioid agonist therapy with methadone or buprenorphine for opioid use disorders, such as heroin addiction, was associated with a...
October 28, 2014

The recent World Hepatitis Day event at the White House presented a terrific opportunity for the nation to focus on the “silent epidemic” of viral hepatitis.

October 27, 2014
A study led by the researcher at the Institute of Biomedical Research (IDIBELL), Isabel Fabregat, could serve to select patients with hepatocellular carcinoma unresponsive to most frequently used...

Pages